Testing a new stomach medicine for heart patients on clopidogrel
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests if a new stomach acid medicine (Zastaprazan) affects how well clopidogrel works in heart patients who have had a stent placed. It aims to help people who need both clopidogrel and a stomach acid drug after a procedure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older.
- You have chronic coronary syndrome (stable heart disease) and have had a stent placed.
- Your doctor plans for you to take clopidogrel (with aspirin) for at least 6 months after the stent.
- You are not allergic to any of the study medicines (stomach acid drugs, aspirin, clopidogrel).
- You have not had stomach surgery that changes acid production (except simple repairs or minor surgeries).
- You do not have certain inflammatory conditions or take HIV medications, and your liver and kidney labs are within a safe range.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way of taking blood thinners after getting a stent. Instead of staying on two blood thinners for a long time, you switch earlier to just one (ticagrelor). This might reduce bleeding risks while still protecting against heart problems.
This trial tests if a newer acid-reducing drug is better than standard care for preventing stomach problems in people who recently had a heart attack and a stent placed. It could help those who need stomach protection while on blood thinners.
This trial tests a new medicine called zastaprazan, which helps reduce stomach acid, to see if it can prevent bleeding in the stomach and intestines for people who are on blood thinners after a stroke. If you are taking blood thinners, this medicine might lower your risk of serious stomach bleeding.
This trial tests whether fexuprazan can prevent upper gastrointestinal bleeding in people at high risk who need two antiplatelet drugs for at least 6 months after a heart stent. If you are on dual antiplatelet therapy after a stent and have risk factors like older age, low weight, or history of ulcers, this study may help protect your stomach.
This phase 1 trial tests a new medicine called IY-828026 in healthy volunteers to see how safe it is and how the body processes it. It's a first step to find the right dose and check for side effects.
This study tests a new medicine called Ilaprazole 10 mg to see if it can prevent stomach ulcers caused by NSAIDs (pain relievers like ibuprofen). If you take NSAIDs regularly and have a higher risk of ulcers, this trial may help protect your stomach.
Hear when a new Chronic Coronary Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.